Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
esophageal cancer
Marketing
BeiGene launches PD-1 drug Tevimbra at 10% discount to Keytruda
The average wholesale acquisition cost of Tevimbra is estimated to be $15,075 per month, a BeiGene spokesperson told Fierce Pharma.
Angus Liu
Oct 4, 2024 10:37am
Lucid recruits NFL alums for esophageal precancer testing blitz
Oct 2, 2024 11:20am
FDA challenges broad use of PD-1 drugs in stomach cancer
Sep 24, 2024 2:30pm
With ODAC, FDA weighs limiting PD-1 drugs in stomach cancer
Aug 22, 2024 3:28pm
Castle Biosciences fortifies esophageal cancer awareness efforts
Apr 11, 2024 12:30pm
BeiGene finally snags FDA approval for PD-1 drug Tevimbra
Mar 15, 2024 8:39am
